麻醉探秘:多发性骨髓瘤是怎么增加局麻药全身毒性反应发生风险的

2022-04-29 梧桐医学 梧桐医学

一文读懂~

『疼痛』对于人类而言,如同敌人一样存在着,它总是折磨着你吃不好,睡不好,无法正常生活。当药物治疗无效时,我们需要进行『疼痛微创治疗』,虽然它可以有效的缓解疼痛,但是万万不可轻视它可能出现的并发症:局『麻药全身毒性(LAST)』

随着影像引导技术的发展,临床医生经验的累积,LAST的发生率已经很低了,但是低不等于零,这仍是一种危及生命的并发症。

比如今日这位中年女性患者,在进行疼痛微创治疗后出现了心动过速、呼吸急促和缺氧等危机症状。究竟是发生了什么呢?

病例
回顾

这是一位有『多发性骨髓瘤(MM)』病史的女性患者,伴有高钙血症和慢性骨痛。多模式镇痛方案和大剂量阿片类药物已经无法控制她的疼痛,因严重的急性疼痛危象入院。

由于疼痛剧烈,患者无法忍受脊柱磁共振(MRI)检查,因此决定MRI之前先进行疼痛介入治疗,以便能够顺利的完成脊柱MRI检查。于是在疼痛门诊X线引导下在L4-L5节段置入硬膜外导管用于姑息疼痛治疗(如图1)

 

图片

图1:X线引导下L4-L5节段置入硬膜外导管

治疗过程

局部使用2ml利多卡因逐层浸润,在确认导管位置后,给予3ml的1%利多卡因和肾上腺素的试验剂量,心率没有发生变化,于是从导管输注8ml的0.25%布比卡因。

进行15分钟的监测后,转移至MRI检查区域,计划在检查之后开始持续的硬膜外药物输注。

在此期间,患者发生LAST,出现心动过速,高血压,呼吸急促,缺氧,SpO2为83%,需要进行气道正压通气。患者被紧急转移到ICU。左侧胸腔穿刺置管引流,排出1L胸水,无并发症发生,并持续滴注利多卡因。

大约15分钟后,与治疗前心电图(如图2)相比,新出现左束支传导阻滞(如图3)。在接下来的20分钟内,患者出现了轻微的心血管系统反应。

图片

图2:治疗前心电图

图片

图3:并发局麻药全身毒性后心电图

在患者近期化疗过程中,使用了类固醇类激素,同时给予了大剂量正性肌力药和血管升压药(多巴酚丁胺10ug/kg/min,肾上腺素0.2ug/kg/min,去甲肾上腺素0.3ug/kg/min,加压素0.04U/min)。

在全身运动功能减退的情况下,超声心动图显示左心室射血分数(LVEF)只有25-30%(正常值为50-70%),未发现局部的心室壁运动异常。

考虑到患者严重的,难以维持的血流动力学障碍和既往使用过布比卡因的情况,LAST发生后先用1.5ml/kg静脉滴注20%脂乳剂,再0.25ml/kg/min静脉滴注,即刻缓解显著。

不久后,患者几乎停止了所有血管活性药物,并且精神状态良好。复查心电图显示窦性心律(如图4)。初次检查TTE后进行复查,双心室功能恢复且LVEF为50%。

图片

图4:滴注脂肪乳剂后心电图恢复窦性心律

最终检查结果显示所有椎体和肋骨广泛性溶骨病变明显加重,与弥漫性骨髓瘤病情一致。此外,L4-L5背侧软组织及L3-L4右侧水平有皮下结节,与皮肤骨髓瘤病情一致(如图5)

 

图片

图5:可见椎体中出现多处溶骨性病变

最后讨论 

『局麻药全身毒性(LAST)』是可危及生命的并发症,在周围神经阻滞中发生率为2.5-9.8/10000,在硬膜外麻醉中发生率为1.2-11次/10000。

患者病情进展和恢复时间线如下所示(如图6)

图片

图6:病情进展和恢复的时间线

LAST | 潜在危险因素
图片

在该病例中,导致心血管系统衰竭的局麻药全身毒性是非常罕见的,但在这种情况下,可能存在潜在的病因。LAST的风险随着局麻药用量、低体重、极限年龄和预先存在的心脏、肝脏、肾脏和代谢功能障碍而增加。

该女性所患原发病:多发性骨髓瘤(MM),也会导致LAST的易感性增加。典型的MM包括肾脏损害,神经病变,静脉血栓栓塞,肝脏受累和溶骨性骨病变。

活跃的MM伴骨髓微血管密度显著增加引起组织代谢紊乱。在本例患者中,CT上可见所有椎体和皮肤骨髓瘤区域的溶解性病变,可能与血管床增加有关。

如何| 降低风险
图片

在任何肿瘤病变部位附近进行局麻药操作都有可能增加LAST的风险,因此需要高度警惕。那么该如何降低LAST发生的风险呢?临床医生可以考虑仅使用阿片类药物向神经周围注射,此外也可选用1%苯海拉明或苯甲醇作为局部浸润的代替药物。

此外,建议在硬膜外和周围神经阻滞注射时使用含有肾上腺素的试验剂量,局麻药避免使用布比卡因,并延长连续监测时间以此来降低使用剂量,从而降低LAST发生的风险。

参考文献:
Victoria M Lim, Taylor Barney, Arun L Jayaraman. Multiple myeloma and malignant lesions:a potential risk factor for local anesthetic systemic toxicity[J]. Reg Anesth Pain Med,fist published as 10.1136/rapm.2021-102845 on 17 September 2021,1-4pages.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2103593, encodeId=14e62103593e8, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb98458401, createdName=ms7000000503957229, createdTime=Wed Nov 30 21:27:53 CST 2022, time=2022-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1890373, encodeId=f97c18903e35c, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Dec 31 13:29:46 CST 2022, time=2022-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663869, encodeId=51bb166386991, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Wed Jun 01 09:29:46 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231733, encodeId=3cf21231e3307, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Mon Jul 11 08:46:46 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215988, encodeId=7e3012159882c, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43116, encryptionId=dd85431162e, topicName=多发性骨髓瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 10:05:34 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215814, encodeId=3f2112158144e, content=这个研究不错,厉害了!!!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65aa5643711, createdName=小白努力长高高, createdTime=Sat Apr 30 14:25:07 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215742, encodeId=a3a31215e4237, content=***,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Apr 30 07:14:14 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215714, encodeId=73541215e1488, content=认真***, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Apr 29 23:20:35 CST 2022, time=2022-04-29, status=1, ipAttribution=)]
    2022-11-30 ms7000000503957229 来自辽宁省

    学到了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2103593, encodeId=14e62103593e8, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb98458401, createdName=ms7000000503957229, createdTime=Wed Nov 30 21:27:53 CST 2022, time=2022-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1890373, encodeId=f97c18903e35c, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Dec 31 13:29:46 CST 2022, time=2022-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663869, encodeId=51bb166386991, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Wed Jun 01 09:29:46 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231733, encodeId=3cf21231e3307, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Mon Jul 11 08:46:46 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215988, encodeId=7e3012159882c, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43116, encryptionId=dd85431162e, topicName=多发性骨髓瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 10:05:34 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215814, encodeId=3f2112158144e, content=这个研究不错,厉害了!!!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65aa5643711, createdName=小白努力长高高, createdTime=Sat Apr 30 14:25:07 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215742, encodeId=a3a31215e4237, content=***,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Apr 30 07:14:14 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215714, encodeId=73541215e1488, content=认真***, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Apr 29 23:20:35 CST 2022, time=2022-04-29, status=1, ipAttribution=)]
    2022-12-31 jml2009
  3. [GetPortalCommentsPageByObjectIdResponse(id=2103593, encodeId=14e62103593e8, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb98458401, createdName=ms7000000503957229, createdTime=Wed Nov 30 21:27:53 CST 2022, time=2022-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1890373, encodeId=f97c18903e35c, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Dec 31 13:29:46 CST 2022, time=2022-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663869, encodeId=51bb166386991, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Wed Jun 01 09:29:46 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231733, encodeId=3cf21231e3307, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Mon Jul 11 08:46:46 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215988, encodeId=7e3012159882c, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43116, encryptionId=dd85431162e, topicName=多发性骨髓瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 10:05:34 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215814, encodeId=3f2112158144e, content=这个研究不错,厉害了!!!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65aa5643711, createdName=小白努力长高高, createdTime=Sat Apr 30 14:25:07 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215742, encodeId=a3a31215e4237, content=***,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Apr 30 07:14:14 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215714, encodeId=73541215e1488, content=认真***, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Apr 29 23:20:35 CST 2022, time=2022-04-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2103593, encodeId=14e62103593e8, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb98458401, createdName=ms7000000503957229, createdTime=Wed Nov 30 21:27:53 CST 2022, time=2022-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1890373, encodeId=f97c18903e35c, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Dec 31 13:29:46 CST 2022, time=2022-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663869, encodeId=51bb166386991, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Wed Jun 01 09:29:46 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231733, encodeId=3cf21231e3307, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Mon Jul 11 08:46:46 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215988, encodeId=7e3012159882c, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43116, encryptionId=dd85431162e, topicName=多发性骨髓瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 10:05:34 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215814, encodeId=3f2112158144e, content=这个研究不错,厉害了!!!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65aa5643711, createdName=小白努力长高高, createdTime=Sat Apr 30 14:25:07 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215742, encodeId=a3a31215e4237, content=***,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Apr 30 07:14:14 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215714, encodeId=73541215e1488, content=认真***, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Apr 29 23:20:35 CST 2022, time=2022-04-29, status=1, ipAttribution=)]
    2022-07-11 屋顶瞄爱赏月

    签到学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2103593, encodeId=14e62103593e8, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb98458401, createdName=ms7000000503957229, createdTime=Wed Nov 30 21:27:53 CST 2022, time=2022-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1890373, encodeId=f97c18903e35c, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Dec 31 13:29:46 CST 2022, time=2022-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663869, encodeId=51bb166386991, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Wed Jun 01 09:29:46 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231733, encodeId=3cf21231e3307, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Mon Jul 11 08:46:46 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215988, encodeId=7e3012159882c, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43116, encryptionId=dd85431162e, topicName=多发性骨髓瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 10:05:34 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215814, encodeId=3f2112158144e, content=这个研究不错,厉害了!!!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65aa5643711, createdName=小白努力长高高, createdTime=Sat Apr 30 14:25:07 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215742, encodeId=a3a31215e4237, content=***,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Apr 30 07:14:14 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215714, encodeId=73541215e1488, content=认真***, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Apr 29 23:20:35 CST 2022, time=2022-04-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2103593, encodeId=14e62103593e8, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb98458401, createdName=ms7000000503957229, createdTime=Wed Nov 30 21:27:53 CST 2022, time=2022-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1890373, encodeId=f97c18903e35c, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Dec 31 13:29:46 CST 2022, time=2022-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663869, encodeId=51bb166386991, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Wed Jun 01 09:29:46 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231733, encodeId=3cf21231e3307, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Mon Jul 11 08:46:46 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215988, encodeId=7e3012159882c, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43116, encryptionId=dd85431162e, topicName=多发性骨髓瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 10:05:34 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215814, encodeId=3f2112158144e, content=这个研究不错,厉害了!!!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65aa5643711, createdName=小白努力长高高, createdTime=Sat Apr 30 14:25:07 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215742, encodeId=a3a31215e4237, content=***,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Apr 30 07:14:14 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215714, encodeId=73541215e1488, content=认真***, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Apr 29 23:20:35 CST 2022, time=2022-04-29, status=1, ipAttribution=)]
    2022-04-30 小白努力长高高

    这个研究不错,厉害了!!!谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2103593, encodeId=14e62103593e8, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb98458401, createdName=ms7000000503957229, createdTime=Wed Nov 30 21:27:53 CST 2022, time=2022-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1890373, encodeId=f97c18903e35c, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Dec 31 13:29:46 CST 2022, time=2022-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663869, encodeId=51bb166386991, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Wed Jun 01 09:29:46 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231733, encodeId=3cf21231e3307, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Mon Jul 11 08:46:46 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215988, encodeId=7e3012159882c, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43116, encryptionId=dd85431162e, topicName=多发性骨髓瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 10:05:34 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215814, encodeId=3f2112158144e, content=这个研究不错,厉害了!!!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65aa5643711, createdName=小白努力长高高, createdTime=Sat Apr 30 14:25:07 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215742, encodeId=a3a31215e4237, content=***,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Apr 30 07:14:14 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215714, encodeId=73541215e1488, content=认真***, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Apr 29 23:20:35 CST 2022, time=2022-04-29, status=1, ipAttribution=)]
    2022-04-30 phoebeyan520

    ***,谢谢

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2103593, encodeId=14e62103593e8, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb98458401, createdName=ms7000000503957229, createdTime=Wed Nov 30 21:27:53 CST 2022, time=2022-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1890373, encodeId=f97c18903e35c, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Dec 31 13:29:46 CST 2022, time=2022-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663869, encodeId=51bb166386991, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Wed Jun 01 09:29:46 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231733, encodeId=3cf21231e3307, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Mon Jul 11 08:46:46 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215988, encodeId=7e3012159882c, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43116, encryptionId=dd85431162e, topicName=多发性骨髓瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 10:05:34 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215814, encodeId=3f2112158144e, content=这个研究不错,厉害了!!!谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65aa5643711, createdName=小白努力长高高, createdTime=Sat Apr 30 14:25:07 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215742, encodeId=a3a31215e4237, content=***,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Apr 30 07:14:14 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215714, encodeId=73541215e1488, content=认真***, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Apr 29 23:20:35 CST 2022, time=2022-04-29, status=1, ipAttribution=)]
    2022-04-29 医鸣惊人

    认真***

    0

相关资讯

BJH:达雷妥尤单抗治疗多发性骨髓瘤的结果:来自加拿大骨髓瘤研究组数据库的回顾性队列研究

达雷妥尤单抗 (dara) 显着改变了多发性骨髓瘤 (MM) 的治疗前景,尤其是在复发环境中。CMRG-DB 的这些回顾性数据表明,当 dara 与早期治疗线联合使用时,结果会更好。

Lancet Oncol: 泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期

泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期。

多发性骨髓瘤治疗中遇上不良反应怎么办?

多发性骨髓瘤是长期斗争的过程,谨遵医嘱,长期服药!

J Clin Oncol:B细胞成熟抗原和CD19嵌合抗原受体T细胞联合治疗多发性骨髓瘤的长期疗效

联合使用抗B细胞成熟抗原和抗CD19嵌合抗原受体T细胞可在难治性或复发性多发性骨髓瘤患者中诱导持久的缓解

复发不再害怕,多发性骨髓瘤有了治疗新选择!

多发性骨髓瘤治疗是长期斗争的过程,即使病情缓解,仍不能放松警惕!